Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TP 1287 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Ewing's sarcoma; Liposarcoma; Malignant melanoma; Medulloblastoma; Neuroblastoma; Prostate cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Synovial sarcoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Sumitomo Pharma America; Sumitomo Pharma Oncology

Most Recent Events

  • 08 Mar 2024 Status changed from recruiting to discontinued.
  • 06 Jun 2023 Phase 1 dose-escalation in solid tumors has completed and TP-1287 is being investigated in a dose expansion cohort in patients with Ewing sarcoma
  • 06 Jun 2023 Trial design of the expansion part, presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top